Integrated DNA Technologies Expands into Clinical Diagnostics

Launches first in vitro diagnostic offerings to accelerate precision medicine

Mar. 23, 2026 at 11:07am

Got story updates? Submit your updates here. ›

Integrated DNA Technologies (IDT), a global genomics leader, has announced the launch of its first in vitro diagnostic (IVD) offerings, Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx. This strategic move marks IDT's entry into the next generation sequencing (NGS) IVD market, reinforcing the company's commitment to quality, regulatory compliance, and clinical impact. By introducing IVD-grade solutions in the US and select European countries, IDT aims to fill a market gap for standardized workflows in oncology diagnostics.

Why it matters

IDT's expansion into the clinical diagnostics space with IVD-grade solutions addresses a critical need among molecular pathology labs for workflows that ensure accuracy, consistency, and a seamless transition from discovery to diagnostics. This move comes at a time when evolving regulatory requirements in the US and Europe are increasing the complexity of the biomarker landscape, and labs are seeking trusted solutions to navigate this changing landscape with high confidence.

The details

The Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx kits are built on IDT's proprietary Anchored Multiplex PCR (AMP™) chemistry for targeted DNA- and RNA-sequencing. The kits include color-coded, technician- and robot-friendly reagents, adapters, and magnetic cleanup beads, and the workflow steps can run in parallel, enabling efficient and simple library preparation. By expanding its product offerings and introducing IVD-grade reagents, IDT aims to address the growing market demand in the clinical space and support labs as they navigate the increasing complexity of biomarker landscapes.

  • IDT announced the launch of its first in vitro diagnostic offerings on March 23, 2026.

The players

Integrated DNA Technologies (IDT)

A global genomics leader that has expanded into the clinical diagnostics space with the launch of its first in vitro diagnostic offerings, Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx.

Ajay Gannerkote

The president of IDT, who stated that the company's belief in precision diagnostics being as reliable as they are innovative is reflected in the launch of these IVD solutions.

Got photos? Submit your photos here. ›

What they’re saying

“At IDT, we believe that precision diagnostics should be as reliable as they are innovative. This launch reflects our commitment to supporting clinical labs with trusted solutions that combine innovative technology, ease-of-use, and regulatory assurance, so clinicians can focus on their mission-critical work to find the right answers across the expanding biomarker landscape.”

— Ajay Gannerkote, President, IDT

What’s next

IDT plans to continue expanding its Archer IVD solutions portfolio with future planned launches based on the foundational, easy-to-use anchored multiplex-PCR technology, with the ultimate goal of open access to the full range of Archer NGS assay capabilities, including novel fusion and complex variant detection for challenging sample types.

The takeaway

IDT's expansion into the clinical diagnostics space with IVD-grade solutions demonstrates the company's commitment to supporting molecular pathology labs with trusted, innovative, and regulatory-compliant workflows. This move aims to address the growing demand for standardized NGS-based diagnostics and help labs navigate the increasingly complex biomarker landscape with confidence.